(4S,5R)-3-(tert-Butoxycarbonyl)-2,2-dimethyl-4-phenyloxazolidine-5-carboxylic Acid

We are (4S,5R)-3-(tert-Butoxycarbonyl)-2,2-dimethyl-4-phenyloxazolidine-5-carboxylic Acid CAS:143527-70-2 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:
(4S,5R)-3-(tert-Butoxycarbonyl)-2,2-dimethyl-4-phenyloxazolidine-5-carboxylic Acid
CAS.NO:143527-70-2
Synonyms:(4S,5R)-3-(tert-Butoxycarbonyl)-2,2-dimethyl-4-phenyloxazolidine-5-carboxylic acid
(4S,5R)-2,2-dimethyl-3-[(2-methylpropan-2-yl)oxycarbonyl]-4-phenyl-1,3-oxazolidine-5-carboxylic acid
Molecular Formula:C17H23NO5
Molecular Weight:321.36800
 
Physical and Chemical Properties:
Density:1.177
Boiling point:459.009ºC
Flash point:231.4ºC
Index of Refraction:1.526
 
Specification:
Appearance:White to pale brown solid
Purity:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:An intermediate in the preparation of potent anticancer drug Paclitaxel

(4S,5R)-3-(tert-Butoxycarbonyl)-2,2-dimethyl-4-phenyloxazolidine-5-carboxylic Acid


Related News: It does not require a production license for the drug substance, and can be produced in an ordinary chemical plant. As long as it reaches a certain level, it can be used for the synthesis of the drug substance.2-methyl-5-(trifluoromethyl)aniline CAS:25449-96-1 It does not require a production license for the drug substance, and can be produced in an ordinary chemical plant. As long as it reaches a certain level, it can be used for the synthesis of the drug substance.Ácido glioxílico CAS:298-12-4 Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).19346-43-1 The drug review center will establish a registration platform and database for APIs, pharmaceutical excipients and pharmaceutical packaging materials, which means that the domestic drug substance DMF system is expected to be gradually implemented.The drug review center will establish a registration platform and database for APIs, pharmaceutical excipients and pharmaceutical packaging materials, which means that the domestic drug substance DMF system is expected to be gradually implemented.

Related Products
Product Name
Methyl 4-[(5-amino-1-methylindol-3-yl)methyl]-3-methoxybenzoate View Details
benzyl N-[(2R)-1-(benzylamino)-3-hydroxy-1-oxopropan-2-yl]carbamate View Details
Cylopropylmethyl chloride View Details
delta-Valerolactone manufacturer oct-7-enoic acid manufacturer N-Boc-glycine Ethyl Ester manufacturer 4-Chloro-1-Butene manufacturer N-[(2R,3S)-2-(2,5-Difluorophenyl)tetrahydro-5-oxo-2H-pyran-3-yl]carbamic acid 1,1-dimethylethyl ester manufacturer